ARTICLE | Clinical News
Tezosentan: Pivotal
February 20, 2001 8:00 AM UTC
Actelion and partner Genentech Inc. (DNA, South San Francisco, Calif.) said that in a pivotal trial of ATLN's tezosentan intravenous dual endothelial receptor antagonist, the compound produced positi...